CTOs on the Move

Counsyl

www.counsyl.com

 
Counsyl is a DNA testing and genetic counseling service that offers genetic screening for men, women and their children. Our philosophy is simple - focus on diseases where advanced knowledge makes a difference in health outcomes, whether it`s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead. Counsyl has screened over 750,000 patients and served over 10,000 health professionals in its modern clinical laboratory. From the purely mechanical to profoundly human, Counsyl strives to make genetic screening truly accessible to everyone. The team consists of world class engineers, scientists and clinical experts as well as a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.counsyl.com
  • 180 Kimball Way
    South San Francisco, CA USA 94080
  • Phone: 888.268.6795

Executives

Name Title Contact Details

Funding

Counsyl raised $80M on 11/06/2017

Similar Companies

BDI Pharma

BDI Pharma is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Austin Weston Center

Austin Weston Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Austin Weston Center is based in Reston, VA. You can find more information on Austin Weston Center at www.austin-weston.com

Aurora Behavioral Health Care

Aurora Behavioral Health Care is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Aurora Behavioral Health Care is based in San Diego, CA. You can find more information on Aurora Behavioral Health Care at www.aurorabehavioral.com

Ipa Independent Pharmacy Co-op

Ipa Independent Pharmacy Co-op is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.